KYMR · Kymera Therapeutics, Inc.
$114.96
-1.74% last session
End-of-day data · close of 2026-09-11
Market cap
$9B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-23.2
Dividend yield
—
Beta
1.96
Avg volume
1M
Employees
0K
Daily Change %
-1.74%
5 Days Change
-0.33%
10 Days Change
-1.72%
30 Days Change
2.60%
60 Days Change
5.98%
Month to Day Change
-1.72%
Year to Day Change
50.37%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KYMR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
Wells Fargo
Overweight$151
+29.1% vs priceBarclays
Overweight$139
+18.8% vs priceDeutsche Bank
Hold$120
+2.6% vs priceRBC Capital
Sector Perform$115
-1.7% vs priceBank of America
Buy$125
+6.8% vs priceUBS
Buy$128
+9.4% vs priceCitigroup
Buy$120
+2.6% vs priceJP Morgan
Overweight$125
+6.8% vs priceJefferies
Buy$122
+4.3% vs priceMorgan Stanley
Overweight$127
+8.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Wolfe Research | Upgrade | Peer Perform → Outperform | $0.00 |
| 2026-08-31 | Guggenheim | Maintains | Buy | $135 → $170 |
| 2026-08-27 | Wells Fargo | Maintains | Overweight | $116 → $151 |
| 2026-08-06 | Barclays | Maintains | Overweight | $133 → $139 |
| 2026-07-30 | Deutsche Bank | Initiates | Hold | $0.00 → $120 |
| 2026-07-28 | Guggenheim | Maintains | Buy | $125 → $135 |
| 2026-07-16 | Mizuho | Maintains | Outperform | $120 → $140 |
| 2026-07-13 | RBC Capital | Downgrade | Outperform → Sector Perform | $106 → $115 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.5% above the 50-day MA ($114.40).
- Price vs 200-day MA: Trading 27.6% above the 200-day MA ($90.11).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.09) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($46.20) and high ($127.31).
KYMR Price Chart
Loading chart for KYMR…
Fundamentals
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 13.5% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$80B 3.2% YTD
ARGX
argenx SE
$62B 17.0% YTD
MRNA
Moderna, Inc.
$57B 363.3% YTD
RVMD
Revolution Medicines, Inc.
$44B 155.3% YTD
ONC
BeOne Medicines Ltd.
$39B 12.5% YTD
RPRX
Royalty Pharma plc
$34B 54.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -37.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.